Identification and validation of an immune-derived multiple programmed cell death index for predicting clinical outcomes, molecular subtyping, and drug sensitivity in lung adenocarcinoma.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Published Date: Apr 2, 2024

Abstract

OBJECTIVES: Comprehensive cross-interaction of multiple programmed cell death (PCD) patterns in the patients with lung adenocarcinoma (LUAD) have not yet been thoroughly investigated.

Authors

  • Chunhong Li
    Central Laboratory, Guangxi Health Commission Key Laboratory of Glucose and Lipid Metabolism Disorders, The Second Affiliated Hospital of Guilin Medical University, Guilin, 541199, Guangxi, China. chunhongli@glmc.edu.cn.
  • Jiahua Hu
    Central Laboratory, Guangxi Health Commission Key Laboratory of Glucose and Lipid Metabolism Disorders, The Second Affiliated Hospital of Guilin Medical University, Guilin, 541199, Guangxi, China.
  • Xiling Jiang
    Department of Stomatology, Chifeng University Affiliated Hospital, Chifeng, China. jiangxiling06@163.com.
  • Haiyin Tan
    School of Medical Laboratory Medicine, Guilin Medical University, Guilin, 541004, Guangxi, China.
  • Yiming Mao
    Department of Thoracic Surgery, Suzhou Kowloon Hospital, Shanghai Jiao Tong University School of Medicine, Suzhou, 215028, China. mym19850126@163.com.

Keywords

External Resources

Popular Topics
Recent Journals